Medpace (NASDAQ:MEDP) Issues FY 2025 Earnings Guidance

Medpace (NASDAQ:MEDP - Get Free Report) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided EPS guidance of 13.760-14.53 for the period, compared to the consensus EPS estimate of 12.741. The company issued revenue guidance of $2.4 billion-$2.5 billion, compared to the consensus revenue estimate of $2.2 billion.

Analysts Set New Price Targets

A number of brokerages have recently commented on MEDP. Barclays initiated coverage on Medpace in a report on Tuesday, June 24th. They set an "equal weight" rating and a $300.00 price target on the stock. Truist Financial decreased their price objective on shares of Medpace from $333.00 to $300.00 and set a "hold" rating for the company in a report on Wednesday, April 23rd. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and decreased their price objective for the company from $370.00 to $328.00 in a report on Monday, April 14th. William Blair reiterated a "market perform" rating on shares of Medpace in a research report on Tuesday, April 22nd. Finally, Mizuho dropped their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 9th. Twelve analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $344.82.

Medpace Trading Down 1.0%

NASDAQ:MEDP traded down $2.99 on Monday, hitting $308.88. 1,057,188 shares of the company's stock traded hands, compared to its average volume of 383,098. Medpace has a 1 year low of $250.05 and a 1 year high of $462.52. The firm has a 50-day moving average price of $307.47 and a 200-day moving average price of $317.86. The company has a market cap of $8.88 billion, a PE ratio of 23.58, a price-to-earnings-growth ratio of 5.64 and a beta of 1.47.

Medpace (NASDAQ:MEDP - Get Free Report) last released its earnings results on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, beating the consensus estimate of $3.01 by $0.09. Medpace had a return on equity of 54.36% and a net margin of 19.31%. On average, research analysts forecast that Medpace will post 12.29 EPS for the current fiscal year.

Insider Activity

In other news, Director Fred B. Davenport, Jr. sold 1,712 shares of the firm's stock in a transaction on Thursday, April 24th. The shares were sold at an average price of $301.82, for a total transaction of $516,715.84. Following the transaction, the director owned 2,998 shares in the company, valued at approximately $904,856.36. This trade represents a 36.35% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Geneos Wealth Management Inc. increased its position in shares of Medpace by 64.9% during the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Medpace by 3.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company's stock worth $24,929,000 after buying an additional 3,010 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in shares of Medpace by 22.1% during the 1st quarter. NewEdge Advisors LLC now owns 1,048 shares of the company's stock worth $319,000 after acquiring an additional 190 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.